Stockscreener 앱 받기
2.48
0.00%
0.00
시간 외 거래:
2.46
-0.02
-0.81%
전일 마감가:
$2.48
열려 있는:
$2.48
하루 거래량:
781.26K
Relative Volume:
0.41
시가총액:
$225.42M
수익:
$70.39M
순이익/손실:
$-43.97M
주가수익비율:
-4.7867
EPS:
-0.5181
순현금흐름:
$-23.85M
1주 성능:
+5.53%
1개월 성능:
+0.81%
6개월 성능:
+54.04%
1년 성능:
+11.71%
1일 변동 폭
$2.46
$2.62
1주일 범위
$2.33
$2.62
52주 변동 폭
$0.9583
$3.87
Codexis Inc Stock (CDXS) Company Profile
명칭
Codexis Inc
전화
650-421-8100
주소
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.48 | 226.33M | 70.39M | -43.97M | -23.85M | -0.5181 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-29 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-07 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-08-07 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2021-04-12 | 개시 | Piper Sandler | Overweight |
| 2021-03-01 | 개시 | Stifel | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-10 | 개시 | The Benchmark Company | Buy |
| 2019-01-17 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 개시 | Stephens | Overweight |
| 2017-10-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-31 | 개시 | Jefferies | Buy |
| 2017-01-26 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 개시 | H.C. Wainwright | Buy |
모두보기
Codexis Inc 주식(CDXS)의 최신 뉴스
CDXS Q1 2026 Earnings: EPS Beats Estimates by 28.26% Despite Revenue UncertaintiesMargin Improvement Report - newsline.com
Codexis (CDXS) Hovers Near Support as Consolidation ContinuesExtension Target - newsline.com
CDXS Stock Price, Quote & Chart - ChartMill
Codexis director Raymond de Vre sells $6,173 in shares - Investing.com UK
Codexis director Raymond de Vre sells $6,173 in shares By Investing.com - Investing.com Nigeria
Codexis (CDXS) director De Vre sells 2,605 shares to cover RSU tax liability - Stock Titan
CDXS Q1 2026 Earnings: EPS Beat Despite Revenue Uncertainty, Shares SlipOperating Income Trends - newsline.com
Why Did CDXS Stock Jump 7% Today? - Stocktwits
CDXS Q1 2026 Earnings: EPS Surprise of 28% Fails to Offset Revenue UncertaintyEarnings Revision Downgrade - newsline.com
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss Signals ProgressProduct Revenue Analysis - newsline.com
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA - Caledonian Record
Codexis Inc. (CDXS) Posts Modest Gains, Hovers Between Key Support and Resistance LevelsSpring Pattern - newsline.com
Codexis Inc. (CDXS) Climbs 4.4% as Shares Approach Key ResistanceIron Condor Alert - The Legal Advocate
CDXS Q1 2026 Earnings: Surprise EPS Beat Despite Revenue UncertaintyEarnings Per Share - thelegaladvocate.com
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesLow Estimate Range - thelegaladvocate.com
Codexis (CDXS) Slides 1.58% as Biotech Stock Tests Key Support at $2.37Growth Factor - The Legal Advocate
Codexis (CDXS) Q1 2026 Earnings: Why the Beat MattersPositive Surprise Momentum - newsline.com
Q1 2026 Codexis Inc Earnings Call Transcript - GuruFocus
Q3 2025 Codexis Inc Earnings Call Transcript - GuruFocus
TradingKey - TradingKey
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - simplywall.st
Number of shareholders of Codexis, Inc. – NASDAQ:CDXS - TradingView
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 - Yahoo Finance
MSN Money - MSN
Codexis, Inc. (NASDAQ:CDXS) Q1 2026 Earnings Call Transcript - Insider Monkey
Craig-Hallum Maintains Codexis(CDXS.US) With Buy Rating, Announces Target Price $9 - Moomoo
Codexis (NASDAQ:CDXS) Issues Quarterly Earnings Results - MarketBeat
Codexis (CDXS) Q1 2026 Earnings Transcript - AOL.com
Codexis (CDXS) Reports Q1 2026 Earnings and Highlights Growth Pr - GuruFocus
Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end - MSN
Codexis (CDXS) Reports Strong Q1 Revenue and Upcoming Data Prese - GuruFocus
Codexis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Codexis (CDXS) Confident in Financial Stability Through 2027 - GuruFocus
Codexis: Q1 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Codexis beats Q1 2026 EPS forecast, stock rises - Investing.com
Earnings call transcript: Codexis beats Q1 2026 EPS forecast, stock rises By Investing.com - Investing.com South Africa
Codexis (NASDAQ:CDXS) Q1 Results Beat Estimates as Company Reaffirms Full-Year Guidance - ChartMill
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
CDXS: Strong Q1 growth and expanding ECO Synthesis platform position the company for robust 2026 performance - TradingView
CDXS: Q1 2026 revenue doubled and gross margin rose to 71%, with ECO Synthesis gaining industry traction - TradingView
Codexis Q1 Earnings Call Highlights - MarketBeat
Codexis says it has cash through 2027 as siRNA plans advance - Stock Titan
Codexis Reports First Quarter 2026 Financial Results - The Manila Times
Codexis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revenue surges as Codexis (CDXS) narrows quarterly loss and manages debt load - Stock Titan
Codexis (NASDAQ: CDXS) Q1 2026 revenue hits $15.2M as net loss shrinks - Stock Titan
Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2026 - marketscreener.com
Opaleye (NASDAQ: CDXS) holds 7.47% of Codexis, 6.785M shares - Stock Titan
Codexis Inc (CDXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Codexis Inc 주식 (CDXS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lutz Stefan | Chief Scientific Officer |
Feb 24 '26 |
Sale |
1.13 |
5,862 |
6,641 |
130,421 |
2.60%
0.94%
자본화:
|
볼륨(24시간):